JAGSONPAL PHARMACEUTICALS LTD.

Jagsonpal Pharmaceuticals Ltd. has entered into a definitive agreement to acquire an 85% equity stake in Aequitas Healthcare Private Limited for ₹20.8 crores. This strategic acquisition marks Jagsonpal's entry into the hospital segment, aiming to strengthen its presence in India's healthcare ecosystem. Aequitas, founded in 2017, focuses on the sale and distribution of pharmaceutical products to hospitals and reported revenues of ₹53 crores in FY26. The transaction, funded by internal accruals, is expected to conclude by July 15, 2026. This move is seen as a transformative pivot for Jagsonpal, shifting from a legacy retail prescription player to an omnichannel specialty healthcare business.

Jagsonpal Pharmaceuticals Ltd has entered into a Share Purchase Agreement (SPA) to acquire 85% of the paid-up equity share capital of Aequitas Healthcare Private Limited for a cash consideration of ₹20.8 Crore. Aequitas Healthcare is engaged in the sale and distribution of pharmaceutical products to hospitals. This acquisition aligns with Jagsonpal's strategic objective to gain access to the hospital channel and institutional doctor network, thereby reducing the time required for organic relationship building. The acquisition is expected to be completed by July 15, 2026, and does not require any governmental or regulatory approvals. Aequitas Healthcare reported a revenue of ₹53.31 crores in FY 2025-26.

Jagsonpal Pharmaceuticals Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This closure is in effect from Wednesday, July 01, 2026, and will remain until 48 hours after the declaration of the unaudited financial results for the quarter ended June 30, 2026. The company will announce the date of the Board Meeting to approve these results in due course. This measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct.

Jagsonpal Pharmaceuticals Ltd. announced the appointment of Mr. Anil Kumar Matai as an Additional Director in the category of Non-Executive Independent Director, effective June 25, 2026, subject to shareholder approval. Mr. Matai brings over three decades of experience in the pharmaceutical and healthcare sectors, having held senior leadership positions focused on strategic growth and operational excellence. His appointment is expected to contribute to the company's growth and value creation for stakeholders. Jagsonpal Pharmaceuticals is a leading player in the Indian pharmaceutical market with a strong portfolio in Gynaecology, Orthopaedics, Dermatology, and Child-care segments.

Jagsonpal Pharmaceuticals Ltd announced the appointment of Mr. Anil Kumar Matai as an Additional Director in the category of Non-Executive Independent Director. The appointment is effective from June 25, 2026, for a term of five years, subject to shareholder approval. Mr. Matai brings over 35 years of experience in the life sciences sector, having held senior leadership roles at Novartis India Ltd., Zydus Healthcare Ltd., and Jashvik Capital. He currently serves as the Director General of OPPI. The company affirmed that Mr. Matai is not disqualified from holding such a position.

Jagsonpal Pharmaceuticals Ltd announced the appointment of Mr. Anil Kumar Matai as an Additional Director in the category of Non-Executive Independent Director. The appointment is effective from June 25, 2026, for a term of five years, subject to shareholder approval. Mr. Matai brings over 35 years of experience in the life sciences and pharmaceutical sectors, having held senior leadership roles including CEO of Novartis India and President & MD of Zydus Healthcare. He is currently the Director General of OPPI. The company affirmed that Mr. Matai is not debarred from directorship by any statutory authority and has no inter-se relationships with existing board members.

Jagsonpal Pharmaceuticals Limited has officially extinguished 16,00,000 equity shares that were acquired through its recent buyback program. This action, in compliance with SEBI regulations, reduces the company's total issued share capital. The pre-buyback share capital stood at 6,71,39,150 equity shares amounting to ₹13,42,78,300. Post-extinguishment, the share capital is now 6,55,39,150 equity shares, valued at ₹13,10,78,300. Depository services have confirmed the extinguishment, and the company has provided necessary certifications as per SEBI's Buyback Regulations.

Pallavi Dinodia Gupta has resigned from her position as an Independent Director of Jagsonpal Pharmaceuticals Ltd, effective May 18, 2026, citing personal reasons. Consequently, she will also step down from her roles in the Audit Committee, Corporate Social Responsibility Committee, and as Chairperson of the Stakeholders Relationship Committee. Gupta has confirmed that there are no other material reasons for her resignation beyond those stated in her resignation letter. She holds directorships in IndiaMART InterMESH Limited, Voith Paper Fabrics India Limited, and Lumax Industries Limited.

Jagsonpal Pharmaceuticals Ltd has announced a buyback offer to repurchase up to 16,00,000 equity shares at a price of ₹250 per share, totaling ₹40 crores. The buyback opens on May 08, 2026, and closes on May 14, 2026. The company has emailed the Letter of Offer to eligible shareholders as of the record date, May 04, 2026, in compliance with Buyback Regulations.

The Board of Directors of Jagsonpal Pharmaceuticals Ltd. has recommended a dividend of ₹4/- per equity share for the financial year ended March 31, 2026. This represents 200% of the face value of ₹2/- per share. The proposed dividend is contingent upon approval by the shareholders at the company's 47th Annual General Meeting. The specific record date and the tentative date for dividend payment will be communicated separately by the company.